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Abstract
Omega-3 fatty acids have long been ascribed a positive cardiovascular func-
tion. However, the plasma measurements invariably ignore 40% of the blood
specimen, cells that engage in continuous exchange with their environment.
In our study, we included all components of the circulating blood. Erythrocyte
or red-blood-cell (RBC) n3 fatty acid status has been linked to cardiovascu-
lar disease and death. A low omega-3 index is an independent risk factor for
cardiovascular disease and mortality. We tested the hypothesis that acute,
maximal exercise would influence the relationship between RBC and serum
fatty acids. RBC fatty acids profiling was achieved using targeted HPLC-MS
mass spectrometry. Healthy volunteers performed maximal treadmill exercise
testing using the modified Bruce protocol. Central hemodynamics were moni-
tored and maximal workload was assessed in metabolic equivalents (METs).
Venous blood was obtained for RBC lipidomics. With the incremental exercise
test, no fatty acid-level variations were found in RBCs, while heart rate and
arterial blood pressure increased significantly. No changes occurred in the
omega-3 quotient, namely the percentage of eicosapentaenoic acid and
docosahexaenoic acid in RBC fatty acids in the RBC membrane. Nonetheless,
maximal (13.50  1.97 METs) exercise intensity led to a decrease of RBC lau-
ric acid (C12:0) in the recovery period. These data suggest that despite signifi-
cant hemodynamic effects, short-term maximal exercise is insufficient to alter
RBC n3 and other fatty-acid status, including the omega-3 quotient, in
healthy individuals. RBC lauric acid deserves further scrutiny as a potential
regulator of cardiovascular and metabolic functions.
Introduction
Erythrocyte or red-blood-cell (RBC) n3 fatty-acid status
is related to health outcomes, including cardiovascular
disease, myocardial infarction, arrhythmias, and sudden
death (Bucher et al. 2002). Fish consumers have less car-
diovascular disease (Huang et al. 2011; InterAct Consor-
tium, 2011). The two most important omega-3 (n3)
polyunsaturated fatty acids are eicosapentaenoic acid
(EPA, C20:5 n3) and docosahexanoic acid (DHA, C22:6
n3). DHA-rich fish oil supplementation favorably mod-
ulates body composition in type-2 diabetic and obese
patients (Mansoori et al. 2015). n3 fatty-acid affect diets
RBC membrane fatty acid composition (Popp-Snijders
et al. 1986). For example, a daily fish-oil concentrate sup-
plement, providing 3 g of omega-3 fatty acids, increases
incorporation of C20:5 omega 3 into RBCs, at the
expense of C18:2 omega 6 fatty acids, but total unsatura-
tion of phospholipids is increased (Cartwright et al.
1985). The n6 fatty acid, linoleic acid (LA), and the
n3 fatty acids, linolenic acid (ALA), eicosapentaenoic
acid (EPA), and docosahexaenoic acid (DHA) collectively
protect against coronary heart disease (Wijendran and
Hayes 2004). The n3 fatty acids, especially EPA and
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DHA, are potent anti-arrhythmic agents (von Schacky
2004; Wijendran and Hayes 2004). Patients with low RBC
n3 and n6 fatty acids, palmitoleic acid, and stearic
acid status have an increased risk of acute coronary syn-
dromes (Shearer et al. 2009). EPA and DHA improve
endothelial function, lower blood pressure, and favorably
act on platelets (Wijendran and Hayes 2004). A low
omega-3 index (the percentage of EPA+DHA in red-cell
lipids) independently increases cardiovascular-disease risk
and mortality (von Schacky 2015; Kleber et al. 2016a,b;
Thuppal et al. 2017). RBC fatty-acid status is particularly
important for assessing disease risk prediction (Kim et al.
2018). During exercise, triacylglycerides, an energy reser-
voir in adipose tissue, are hydrolyzed to free fatty acids,
which are then released to the circulation, providing a
fuel for working muscles (Mika et al. 2019). The most
consistently observed effect has been an increase in the
relative amount of unsaturated, especially monounsatu-
rated, non-esterified fatty acids in plasma after acute exer-
cise, such as running, cycling, or swimming of moderate
intensity for 0.5–2 h per bout (Nikolaidis and Mougios
2004). These exercise-related changes in fatty acid meta-
bolism in adipose tissue and circulating blood could con-
tribute to beneficial cardiovascular and metabolic effects
of physical activity. We tested the hypothesis that acute,
maximal exercise would influence the relationship
between RBC and serum fatty acids (Fig. 1).
Methods
The Charite University Medicine institutional review board
on the use of humans in research approved the study and
written informed consent was obtained. The study was duly
registered: ClinicalTrials.gov Identifier: NCT03121885,
https://clinicaltrials.gov/ct2/show/NCT03121885. Recruit-
ment was primarily via person-to-person interview. Prior
to participation in the study, six healthy volunteers (five
male and one female) signed informed consent forms
which outlined the procedures to be taken and the possible
risks involved. The age of the subjects was 38  15 years.
The body mass index of the individuals was 27.9  6.6 kg/
m2. All subjects were non-trained. They were not taking
medications. Following a routine physical examination at
baseline levels, each subject underwent a maximal treadmill
Bruce test, which is recommended by guidelines for ergom-
etry of the German Society of Cardiology (Bruce et al.
1973; Trappe and Lollgen 2000). The test was preceded by
2 9 3 min warm up periods (stages 1 and 2 of the Bruce
protocol) during which treadmill speed was maintained at
a constant speed of 2.7 km/h and at zero or 5% grade.
Treadmill speed and grade were then increased at three
min intervals to a maximum of 20% grade at 8.8 km/h.
Workload was assessed in metabolic equivalents (METs)
from 5–18 METS. The test was terminated when the sub-
jects informed the investigator that they could no longer
proceed.
Heart rates were monitored continuously by heart-rate
monitor worn around the subject’s torso (Polar T31,
Polar Electro, Kempele, Finland) throughout the tests.
Arterial pressure was measured in each subject while sit-
ting prior to the exercise test (10 min), after termina-
tion of the test (exhaustion), and 10 min recovery after
the end of the running test via a sphygmomanometer
(Critikon, Inc., Johnson & Johnson, New Jersey), which
comprised an inflatable (Riva-Rocci) cuff placed around
the upper arm. Venous blood was collected from a cathe-
ter placed in a contralateral forearm vein (i.e. the antecu-
bital vein) of each subject in the sitting position prior to
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Figure 1. Schematic illustration of the hypothetic influence of short-term maximal exercise associated with increased vasopressor and shear
stress, red blood cell (RBC)-endothelial interactions, and tissue hypoxia facilitating release of oxygen from RBCs on relative EPA+DHA content in
RBC, i.e. omega-3- quotient, which is the percentage of EPA+DHA in red cell fatty acid lipids.
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the exercise test (10 min), after termination of the test
(exhaustion), and 10 min recovery after the end of the
running test (Fig. 2). An additional blood sample was col-
lected in each subject during running when the heart rate
reached 150 beats per minute. We did not measure blood
pressure at this time point (HF 150) because valid blood
pressure measurements could not be obtained during
running using the above sphygmomanometer. All samples
were analyzed for RBC total fatty acids status and plasma
free fatty acids. RBC free fatty acid status was determined
at rest and at maximal workload. RBCs were separated
from EDTA blood by centrifugation and total fatty acids
in RBCs or plasma were determined by liquid chromatog-
raphy mass (HPLC-MS) spectrometry described in (Fis-
cher et al. 2014). Serum lactate was determined in blood
samples obtained from ear lobe at rest and at maximal
workload.
We performed sample size calculation for a difference
in means in omega-3 quotients. We found that our study
would require a sample size of 5 (number of pairs) to
achieve a power of 80% and a level of significance of 5%
(two sided), for detecting a mean of the differences of
0.021 (Harris et al. 2017) between pairs, assuming the
standard deviation of the differences to be 0.88 (Fischer
et al. 2014). Thus, in our sample size calculation, statisti-
cal significance and clinical significance both were taken
into account.
Descriptive statistics were calculated and variables were
examined for meeting assumptions of normal distribution
without skewness and kurtosis. In order to determine sta-
tistical significance between the trials at the various time
intervals, one-way repeated measures analysis of variance
(ANOVA) was conducted and the 0.05 level of signifi-
cance (P) was chosen. The analysis included Mauchly’s
test of sphericity followed by applying the test of within
subjects’ effects with Greenhouse–Geisser correction to
ensure sphericity assumption. When significant differences
were found, Tukey’s honestly-significant-difference post-
hoc test was used for pairwise comparisons. Planned
hypotheses (one-tailed or two-tailed paired t-tests as
appropriate) were tested to follow up the initial ANOVA
findings. All data are presented as mean  SD. All statis-
tical analyses were performed using SPSS Statistics soft-
ware (IBM Corporation, Armonk, NY) or All-Therapy
statistics beta (AICBT Ltd, Vancouver, Canada).
Results
The hemodynamic and lactate values (Table 1) confirmed
maximal exertion. The values include measurements prior
to the exercise test (10 min, rest), after termination of
the test (exhaustion), and 10 min after the end of the
running test (recovery period). An additional blood sam-
ple was collected in each subject during running when the
heart rate reached 150 beats per minute. Exercise induced
an increase in both heart rate and systolic blood pressure,
which normalized to baseline (resting) levels in the recov-
ery period. All individuals terminated exercise at a maxi-
mal workload of 13.50  1.97 METs (Bruce stages
6.33  0.82). Our ANOVA analysis showed that there
were differences between heart rate and systolic blood
pressure at the different time points: rest (baseline),
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Figure 2. Schematic illustration of the experimental protocol used. HF, heart rate; BP, blood pressure; RBC, red blood cell; FFA, free fatty acid;
FA, fatty acid; FAomics; plasma fatty acid lipidomics. METs, metabolic equivalents of task.
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exhaustion and recovery (Table 1). At this maximal work-
load, heart rate, systolic and diastolic blood pressure
increased from 71 (baseline) to 185 beats per min from
135 to 190 mmHg and from 81 to 91 mmHg respectively
(P < 0.0001 each, Tukey’s honestly-significant-difference
post-hoc tests, Table 1). Lactate levels were determined at
rest and exhaustion. Lactate levels increased from
1.38  0.30 mmol/L to 9.49  2.10 mmol/L (P < 0.0001,
t-test, Table 1).
Since the impact of acute exercise on individual RBC
fatty acids is unknown, we used an explorative statistical
approach on measured fatty acid profiles, ranging from
C12:0 to C22:6 n3 fatty acids (Table 2), at the different
time points: rest (baseline), the time when heart rate
reached 150 beats per min, exhaustion and recovery. Our
ANOVA analysis showed that there were no differences
between the individual RBC fatty acids of all four groups.
Our ANOVA analysis also showed that there were also no
differences between omega-3 quotients of all four groups
(Table 3). The RBC omega-3 quotients at rest and
exhaustion were 0.067and 0.063 respectively (n = 6,
P = 0.148, t-test). The data indicate that the short-term
maximal exercise is insufficient to alter RBC fatty acid
status repeatedly measured during maximal exercise and
Table 1. Effects of exercise on hemodynamics and lactate (means  SD, n = 6).
Parameter
Time point 1
(rest)
Time point 2
(HF 150)
Time point 3
(exhaustion)
Time point 4
(recovery)
Mauchly’s test,
P value
Greenhouse–Geisser,
P value
t-Test,
P value
Heart rate
(beats per min)
71  10 150 185  6 94  11 <0.001 <0.001
Systolic arterial
blood pressure
(mm Hg)
135.3  9.1 n.d. 190.3  16.6 127.5  13.1 <0.001 <0.001
Diastolic arterial
blood pressure
81.2  14.4 n.d. 90.7  16.4 76.3  10.2 0.065 0.097
Lactate (mmol/L) 1.38  0.30 n.d. 9.49  2.10 n.d. <0.001
Table 2. Lipidomics of RBCs in response to exercise (n = 6).
Fatty acid
(lg/g)
Time point 1
(rest)
Time point 2
(HF 150)
Time point 3
(exhaustion)
Time point 4
(recovery)
Mauchly’s
test,
P value
Greenhouse–Geisser,
P value
C12:0 1.033  1.677 2.060  2.505 1.638  1.837 0.102  0.250 0.411 0.296
C14:0 16.296  12.774 16.147  2.943 23.435  10.156 14.890  8.277 0.234 0.271
C14:1 0.965  0.230 1.048  0.122 1.278  0.448 1.176  0.413 0.079 0.201
C16:0 551.129  158.224 630.805  160.504 601.531  117.900 526.699  101.248 0.512 0.355
C16:1 16.427  6.420 17.171  2.651 21.676  5.304 17.686  5.453 0.622 0.248
C18:0 349.925  102.151 441.744  156.675 379.324  108.094 326.366  79,891 0.258 0.202
C18:1 cis 369.359  109.595 372.508  83.028 386.719  49.709 352.496  70.850 0.784 0.660
C18:1 trans 11.990  3.208 13.388  3.860 14,371  38042 12,703  28,339 0.110 0.444
C18:2 378,376  1172,868 382.639  72.9316 420.356  52.0496 371.114  82.9781 0.940 0.462
C18:3 n3 8.298  2.8805 8.663  2.2216 10.110  2.5471 8.355  1.9315 0.541 0.138
C18:3 n6 3.436  1.1632 3.693  1.009 4.287  1.090 3.521  0.630 0.981 0.145
C20:1 12.580  4.273 11.799  2.585 12.157  1.821 10.424  2.448 0.620 0.295
C20:3 73.136  32.1532 65.684  23.583 68.295  21.397 61.948  24.819 0.193 0.264
C20:4 n3 2.538  1.449 2.355  1.189 2.561  1.185 2.213  1.160 0.442 0.262
C20:4 n6 442.260  116.511 465.333  85.263 459.271  56.357 431.627  87.459 0.149 0.629
C20:5 n3
(EPA)
21.916  5.707 23.876  5.821 24.717  3.954 21.794  3.076 0.432 0.391
C22:1 0.810  0.329 0.873  0.282 0.776  0.178 1.307  1.033 0.001 0.345
C22:5 n3 29.426  5.518 29.755  3.613 30.117  4.364 27.642  3.240 0.288 0.597
C22:5 n6 7.454  2.019 7.277  1.107 7.362  1.287 6.858  1.664 0.398 0.566
C22:6 n3
(DHA)
145.677  57.864 137.331  42.755 138.461  34.927 129.536  48.290 0.631 0.329
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post exercise periods in healthy individuals, including
omega-3 quotients.
High levels of oleic acid (OA, C18:1 cis), palmitic acid
(C16:0), palmitoleic acid (C16:1), and alpha-linolenic acid
(C18:3 n3) in RBCs have been found to associate with
all-cause and cardiovascular mortality (Delgado et al.
2017) or sudden cardiac death (Lemaitre et al. 2009,
2010). Our study revealed no change in levels of fatty
acids C16.0, C16:1, C18:1, and C18:3 n3 in RBCs at
maximal exercise (for all P > 0.05, t-tests).
We next focused on lauric acid (C12:0), which accu-
mulates in blood under exhaustive exercise or in ischemia
(Di Paola and Lorusso 2006) and is an “exchangeable” or
“reversibly-bound” free fatty acid in RBCs (Spector et al.
1972) belonging to medium-chain fatty acids preferen-
tially oxidized in mitochondria in comparison with long-
chain fatty acids (Di Paola and Lorusso 2006). We there-
fore hypothesized that RBC lauric acid levels at maximal
exercise will decrease in the recovery period. Our results
show that RBC lauric acids at exhaustion decreased from
1.638  1.837 to 0.102  0.250 lg/g in the recovery per-
iod (n = 6, P = 0.035, t-test). This effect was associated
with a reduction of heart rate from 185  6 to 94  11
beats per minute (P < 0.001, Tukey’s honestly-significant-
difference post-hoc test). It was also associated with a
decrease of systolic and diastolic blood pressures from
190.3  16.6 to 127.5  13.1 mmHg and from 90.7 
16.4 to 76.3  10.2 mmHg, respectively (P < 0.001 each,
Table 3. Omega-3 quotient of RBCs in response to exercise (means  SD, n = 6).
Fatty acid (lg/g)
Time point 1
(rest)
Time point 2
(HF 150)
Time point 3
(exhaustion)
Time point 4
(recovery)
Mauchly’s
test,
P value
Greenhouse–
Geisser,
P value
C20:5 n3 (EPA) +
C22:6 n3 (DHA)
167.593  63.295 161.207  46.482 163.179  36.480 151.330  50.757 0.65 0.42
Total fatty acids 2443.031  693.691 2634.149  535.512 2608.440  343.774 2328.457  445.098 0.65 0.42
[C20:5 n3 (EPA) +
C22:6 n3 (DHA)] /
Total fatty acids
0.0670  0.0087 0.0610  0.0119 0.0631  0.0129 0.0641  0.0135 0.77 0.09
Table 4. Circulating plasma free fatty acids in response to exhaustive exercise (n = 6).
Free fatty
acid (lg/mL) Time point 1 (rest)
Time point 2
(HF 150)
Time point 3
(exhaustion)
Time point 4
(recovery)
Mauchly’s
test,
P value
Greenhouse–Geisser,
P value
C12:0 8.823  9.831 9.168  8.978 9.542  10.393 10.623  11.010 0.316 0.413
C14:0 44.312  10.303 47.071  14.788 49.479  8.381 51.962  13.056 0.154 0.397
C14:1 2.621  0.964 2.702  1.171 2.515  0.575 3.006  1.039 0.270 0.463
C16:0 331.130  41.900 341.226  25.159 347.013  47.183 373.464  42.320 0.687 0.182
C16:1 40.836  10.314 41.121  6.758 39.598  10.293 42.831  10.876 0.623 0.676
C18:0 150.108  23.790 156.811  11.718 157.947  25.934 171.468  22.982 0.818 0.160
C18:1 cis 283.376  44.731 284.895  25.185 282.537  50.712 306.409  39.356 0.634 0.360
C18:1 trans 21.296  9.985 21.123  6.187 22.490  9.685 24.338  8.694 0.177 0.447
C18:2 328.375  59.582 343.606  22.969 333.085  68.081 366.570  46.221 0.588 0.415
C18:3 n3 10.732  2.374 11.089  3.406 10.636  3.306 11.823  2.722 0.440 0.522
C18:3 n6 5.223  2.052 5.201  1.484 4.922  1.967 5.263  1.451 0.242 0.767
C20:1 10.330  2.172 10.007  2.427 8.119  4.589 10.717  2.580 0.229 0.227
C20:3 50.696  25.737 52.777  28.062 51.191  32.891 55.044  33.320 0.004 0.617
C20:4 n3 2.370  1.219 2.571  1.242 2.583  1.561 2.674  1.441 0.158 0.338
C20:4 n6 139.153  28.757 147.097  18.035 139.433  33.707 148.975  24.443 0.192 0.617
C20:5 n3 (EPA) 15.563  7.039 16.761  8.005 15.812  8.577 16.580  7.211 0.025 0.644
C22:1 0.609  0.201 0.583  0.146 0.612  0.286 0.660  0.139 0.112 0.637
C22:5 n3 6.968  2.003 7.380  1.419 6.786  2.194 7.303  1.606 0.011 0.641
C22:5 n6 2.353  0.613 2.476  0.436 2.307  0.880 2.533  0.784 0.079 0.618
C22:6 n3 (DHA) 43.766  18.081 47.528  18.181 46.919  23.502 48.283  21.276 0.059 0.493
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Tukey’s honestly-significant-difference post-hoc tests),
which indicates possible involvement of this fatty acid in
hemodynamic and metabolic recovery after short-term
maximal exercise.
To provide insights into possible mechanisms underlying
effects of exhaustive exercise on individual RBC fatty acids
status, we measured circulating plasma free fatty acids
(Table 4). The results show that plasma levels of the free fatty
acids C16:0, C16:1, C18:0, C18:1 cis, and C18:2 are relatively
high, whereas levels of C12:0, C14:1, C18:3 n6, C20:4 n3,
and C22:1 are relatively low. Besides lauric acid (C12:0), none
of the circulating free fatty acids did change during exercise
and post exercise. We also measured free fatty acids in RBCs
(Table 5). The results show that free levels of fatty acids in
RBCs are very low, i.e. ~1–2% of the respective individual
total RBC fatty acids. None of the free fatty acids in RBCs did
change during exercise (Table 6). Post exercise circulating
plasma level of lauric acid (10.623  11.010 lg/mL) did not
differ from circulating levels measured at exhaustion
(9.542  10.393 lg/mL, n = 6, P = 0.081, t-test).
Discussion
To our knowledge, this study is the first to assess the
impact of acute exercise on individual RBC fatty acids.
RBC fatty acid profiling was performed on venous blood
taken form healthy subjects undergoing maximal tread-
mill exercise testing using the standard Bruce protocol,
which is used in clinical routine as cardiac stress test to
induce strong and robust increases in heart rate and
blood pressure (Bruce et al. 1973; Trappe and Lollgen
2000). Although we did not confirm our hypothesis that
RBC fatty acids, including the omega-3 quotient, vary
during exercise and/or post-exercise (with exception of
RBC lauric acid), we observed significant increases in
heart rate, blood pressure and lactate in the volunteers at
maximal exercise, which occurred at 13.5 METs. Further-
more, the omega-3 quotient did also not vary during
maximal exercise in healthy volunteers. Finally, short-
term exhaustive exercise did not induce increased mobi-
lization of individual free fatty acids into plasma or
greater rate of oxidation of the free fatty acids removed
from the circulating blood during exercise.
Omega-3 fatty acids
The clinical impact of the omega-3 quotient is well-estab-
lished. Omega-3 index is associated with increased insulin
sensitivity and more favorable metabolic profile in mid-
dle-aged overweight men (Albert et al. 2014) and obese
children (Burrows et al. 2011). A higher omega-3 index is
associated with older age, increasing body mass index,
and a history of smoking and fish oil intake in patients
with peripheral artery disease (Nosova et al. 2014). RBC
n6 fatty acids have been found to be positively associ-
ated, and RBC n3 fatty acids are inversely associated
with body weight gain (Wang et al. 2016). Interestingly,
we did not detect changes in alpha-linolenic acid, which
is inversely related to development of adiposity, at least in
school-age children (Perng et al. 2015). Dietary omega-3
Table 5. Free fatty acids compared to total fatty acids in RBCs at rest (Time point 1; n = 6).
Fatty acid (lg/g) Free fatty acids in RBCs Total fatty acids in RBCs Percentage of free fatty acids (%)
C12:0 0.135  0.043 1.033  1.677 13.1
C14:0 0.505  0.254 16.296  12.774 1.99
C14:1 0.027  0.014 0.965  0.230 2.8
C16:0 3.020  0.221 551.129  158.224 0.5
C16:1 0.232  0.154 16.427  6.420 1.4
C18:0 7.420  1.697 349.925  102.151 2.1
C18:1 cis 1.615  0.662 369.359  109.595 0.4
C18:1 trans 0.141  0.083 11.990  3.208 1.2
C18:2 0.508  0.291 378,376  1,172,868 1.3
C18:3 n3 0.150  0.149 8.298  2.8805 1.8
C18:3 n6 0.018  0.012 3.436  1.1632 0.5
C20:1 0.055  0.048 12.580  4.273 0.4
C20:3 n6 0.025  0.018 73.136  32.1532 3.4
C20:4 n6 0.278  0.098 442.260  116.511 6.2
C20:5 n3 (EPA) 0.037  0.005 21.916  5.707 1.3
C22:1 n9 0.010  0.011 0.810  0.329 1.2
C22:5 n3 0.673  0.542 29.426  5.518 2.3
C22:5 n6 0.298  0.330 7.454  2.019 3.9
C22:6 n3 (DHA) 0.085  0.110 145.677  57.864 5.8
2019 | Vol. 7 | Iss. 8 | e14040
Page 6
ª 2019 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
Exercise, Fatty Acids, and Erythrocytes B. Gollasch et al.
fatty acids modulate the eicosanoid profile in man pri-
marily via the CYP-epoxygenase pathway, which could
function as mediators of the vasodilatory and cardiopro-
tective effects of omega-3 fatty acids (Fischer et al. 2014).
Recent results demonstrate that CYP enzymes efficiently
convert EPA and DHA to novel epoxy and hydroxy
metabolites that could mediate some of the beneficial car-
diovascular effects of dietary omega-3 fatty acids (Arnold
et al. 2010). In recent randomized, double-blind, placebo-
controlled trials, dietary n3 fatty acid supplementation
(3–6 g daily) mitigated the course of coronary atheroscle-
rosis in humans (von Schacky et al. 1999), but had (1 g
daily) no cardiovascular benefit in initially healthy adults
and in patients with diabetes mellitus (Group et al. 2018;
Manson et al. 2018). Nevertheless, recent data show that
dietary EPA (4 g daily, REDUCE-IT trial) is effective for
prevention of major coronary events in hypercholestero-
laemic patients (Yokoyama et al. 2007) and cardiovascular
events in patients with established cardiovascular disease
or with diabetes and other risk factors (Bhatt et al. 2018).
Our results support the concept that the omega-3- quo-
tient is strongly affected by diet, e.g. DHA/EPA-rish fish
oil, but not acute maximal exercise.
Omega-9 fatty acids
High levels of omega-9 monounsaturated fatty acids, oleic
acid (OA, C18:1 cis), gondoic acid (GA, C20:1), and
nervonic acid (NA, C24:1) in RBCs showed increased all-
cause and cardiovascular mortality in the Ludwigshafen
Risk and Cardiovascular Health Study (Delgado et al.
2017). High levels of palmitic acid (C16:0) palmitoleic
acid (C16:1), oleic acid (C18:1), and alpha-linolenic acid
(C18:3 n3) were also associated with higher risk of sud-
den cardiac death (Lemaitre et al. 2009, 2010). Our study
revealed a tendency towards elevated levels of the fatty
acids C16.0, C16:1, C18:1, and C18:3 n3 in RBC at
exhaustion, but the effects were not statistically signifi-
cant. Future studies are warranted to explore biologic and
prognostic properties of omega-9 fatty acids in long-term
effects on cardiovascular disease.
Lauric acid
Lauric acid (C12:0) is the primary fatty acid found in
coconut oil. High-coconut Nourish and high-virgin coco-
nut oil diets improve cardiovascular and liver complica-
tions in obesity in rats (Panchal et al. 2017). RBCs have
at least two classes of fatty acid binding sites for laurate
and possibly other medium-chain fatty acids (Spector
et al. 1972). The stronger class has approximately
1.2 9 105 sites/cell and an association constant for laurate
of 1.8 9 106 mol/L. These strong sites probably bind
much of the “nonexchangeable” or “irreversibly bound”
free fatty acid pool of the cell. The large, weaker class of
binding sites contains approximately 8.0 9 106 sites/cell
Table 6. Free fatty acids in RBCs in response to exercise (n = 6).
Fatty acid (lg/g) Time point 1 (rest) Time point 3 (exhaustion) t-test, P value
C12:0 0.135  0.043 0.127  0.049 0.76
C14:0 0.505  0.254 0.405  0.108 0.39
C14:1 0.027  0.014 0.022  0.012 0.51
C16:0 3.020  0.221 2.945  0.275 0.614
C16:1 0.232  0.154 0.135  0.014 0.16
C18:0 7.420  1.697 7.658  1.929 0.82
C18:1 cis 1.615  0.662 1.297  0.328 0.32
C18:1 trans 0.141  0.083 0.080  0.028 0.11
C18:2 0.508  0.291 0.363  0.080 0.27
C18:3 n3 0.150  0.149 0.087  0.041 0.34
C18:3 n6 0.018  0.012 0.013  0.005 0.36
C20:1 0.055  0.048 0.035  0.014 0.35
C20:2 n6 0.023  0.023 0.017  0.008 0.52
C20:3 n6 0.025  0.018 0.017  0.005 0.29
C20:4 n6 0.278  0.098 0.225  0.033 0.23
C20:5 n3 (EPA) 0.037  0.005 0.030  0.006 0.07
C22:1 n9 0.010  0.011 0.007  0.005 0.51
C22:5 n3 0.673  0.542 0.432  0.109 0.29
C22:5 n6 0.298  0.330 0.160  0.039 0.33
C22:6 n3 (DHA) 0.085  0.110 0.043  0.012 0.38
C24:1 n9 0.127  0.134 0.098  0.053 0.64
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and has an association constant for laurate of
1.3 9 104 mol/L. The fatty acid present at these sites
probably represents the “exchangeable” or “reversibly-
bound” free fatty acid pool of the cell (Spector et al.
1972). The observed post exercise decrease in RBC lauric
acid (C12:0) could contribute to gain access to the lipid
energy reserves in skeletal muscle, liver, and heart (Di
Paola and Lorusso 2006; Exercise-induced 2017), where
medium-chain fatty acids appear to be preferentially oxi-
dized in mitochondria compared to long-chain fatty
acids. Since circulating C12:0 plasma levels and free C12:0
levels in RBCs were not affected by exercise, the decrease
of total RBC lauric acid is possibly caused from its
“nonexchangeable” or “irreversibly bound” free fatty acid
pool in the red blood cells. The functional importance
and downstream effects of lauric acid in metabolic and
hemodynamic post exercise recovery remain to be deter-
mined.
Exercise protocol considerations
The modified Bruce protocol was selected to ensure that
all subjects were able to complete a similar highest inten-
sity workload (13.50  1.97 METs) concomitant with
robust and significant short-term increases in heart rate
and blood pressure without fatiguing. For consistency, we
used also an intermediate workload (10.00  1.90 METs,
P = 0.0009, t-test) reaching a heart rate of 150 or more
beats per min to ensure that all runners could complete
the test with marked increases in heart rate and blood
pressure without fatiguing. Our clinical data show that
the exercise protocol caused the expected hemodynamic
and metabolic changes in the subjects under study.
Limitations
We obtained venous blood from an arm vein, although
the source free and RBC fatty acids, if modified from
exercising muscle and its vasculature, suggests that the leg
would provide a different measure. However, blood sam-
ples were taken from the arm vein because of the great
difficulty associated with obtaining blood from a vein in
dynamically contracting leg muscles. Therefore, stronger
effects may have been present in the venous effluent of
the exercising muscle (Giordano et al. 2011). We studied
effects of maximal short-term exercise, but not endurance
exercise, which may also lead to different results. Interest-
ingly, elite athletes have an increased incidence of sudden
death and low omega-3-quotients (von Schacky et al.
2014). However, it is unknown whether this deficiency in
omega-3-quotient results from reduced diet or extreme
endurance exercise training.
Conclusions
Our results suggest that dynamic exercise does not change
the levels of RBC n3 fatty acid status in the systemic cir-
culation. Our results are consistent with the idea that the
essential fatty acids (n3 and n6) are strongly affected by
diet (Fischer et al. 2014), but not short-term maximal exer-
cise, whereas changes in RBC lauric acid, which can be syn-
thesized de novo and is bound in red blood cells, reflects
metabolic processes. More research is needed to determine
the contribution of RBC fatty acids to cardiac performance
and regulation of coronary and/or skeletal-muscle blood
flow in health and cardiovascular disease.
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